STAG2 and melanoma: Consistently, melanoma cell lines (A375, Mel1617, WM902, WM983, and M14) resistant to BRAFi or MEKi showed reduced expression of STAG2 and STAG3, and their KD led to a further decrease of DUSP6 as well as of BRAFi sensitivity, along with an increase in ERK1/2 phosphorylation.